CN100377718C - Alcohol-neutralizing agent composition containing hyaluronic acid - Google Patents

Alcohol-neutralizing agent composition containing hyaluronic acid Download PDF

Info

Publication number
CN100377718C
CN100377718C CNB2005100933419A CN200510093341A CN100377718C CN 100377718 C CN100377718 C CN 100377718C CN B2005100933419 A CNB2005100933419 A CN B2005100933419A CN 200510093341 A CN200510093341 A CN 200510093341A CN 100377718 C CN100377718 C CN 100377718C
Authority
CN
China
Prior art keywords
hyaluronic acid
present
mucosa
agent composition
alcoholism
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB2005100933419A
Other languages
Chinese (zh)
Other versions
CN1732981A (en
Inventor
凌沛学
庞晓阳
荣晓花
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CNB2005100933419A priority Critical patent/CN100377718C/en
Publication of CN1732981A publication Critical patent/CN1732981A/en
Priority to JP2008527293A priority patent/JP2009505992A/en
Priority to PCT/CN2006/002190 priority patent/WO2007022734A1/en
Application granted granted Critical
Publication of CN100377718C publication Critical patent/CN100377718C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/44—Elemental carbon, e.g. charcoal, carbon black
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to an antialcoholic agent composition containing hyaluronic acid, which belongs to the technical field of medicines or health care food and is prepared from the basic components of hyaluronic acid and activated carbon. The antialcoholic agent composition of the present invention takes the basic components as a base on which other active ingredients and auxiliary material ingredients can be added to prepare any preparations for administration. Every 100g of the composition of the present invention contains 0.001 to 99.9g of hyaluronic acid and 0.001 to 99.9g of activated carbon. The antialcoholic agent composition of the present invention is conspicuously characterized in that hyaluronic acid and activated carbon cooperatively performance strong effect on the adsorption of alcohol (ethanol), and human bodies' absorption of alcohol is conspicuously reduced, so that injuries caused by excessive drinking to the tissue and the organs of human bodies are conspicuously alleviated; simultaneously, the mucosa protecting function and the mucosa repair promoting function of hyaluronic acid can be performed, so that the present invention takes effect on protecting and promoting the repair of intestine mucosa, stomach mucosa and the mucosa of other injured parts; the present invention takes conspicuous effect by being administrated both before and after drinking, and is an ideal antialcoholic agent composition.

Description

Contain hyaluronic Medicament for Alcoholism combination
Technical field
The invention belongs to medicine or health food technology field, is a kind of Medicament for Alcoholism combination that contains hyaluronic acid (English: hyaluronic acid claims glass acid again).
Background technology
Illness such as excessive consumption of alcohol and the liver that causes thus, the intestines and stomach, brain have become one of present key factor that influences human health.For example, have approximately traffic accident over half, fall down in addition death all with drink relevant; Excessive consumption of alcohol can make athero cause fatty liver, gastric ulcer even gastrorrhagia thereby crisis life at liver, also can cause nervous system damage and cerebral cortex atrophy etc., and have a strong impact on family life.However, the people of excessive consumption of alcohol even excessive drinking but also grows with each passing day.At present, the non-specific antidotal therapy of the many employings of poisoning that causes for excessive consumption of alcohol is then many based on nutritional supplementation for the treatment of alcoholic hepatic injury, gastric injury and brain injury clinically, and generally speaking, many based on remedying after poisoning or the damage, can not tackle the problem at its root.This shows, develop that Medicament for Alcoholism is extremely urgent safely and effectively.Can reduce the absorption of human body by Medicament for Alcoholism to ethanol (ethanol), and the minimizing that human body absorbs ethanol, then wine means the reduction of ethanol to human toxicity and damage.Patent (application number: 99115817.2) proposed the application of active carbon as Medicament for Alcoholism, this patent shows, active carbon can utilize impurity and alcohol component in its highly developed gap structure sorbing liquor, to preventing drunk and alleviating the symptom of being still drank after a night after drinking remarkable effect is arranged.But simple applied activated carbon; its antialcoholism action is limited, because the retention time at stomach is shorter behind the active carbon oral, has influenced the amount of its absorption ethanol; and concerning the people who intestine gastric ulcer occurs, take active carbon merely to not protection and repair of gastrointestinal mucosa.This shows that ideal Medicament for Alcoholism is to possess following 2 characteristics: (1) can adsorb ethanol comprehensively, obviously reduce the absorption of ethanol and absorb organ and the tissue injury caused because of whole body; (2) can protect gastrointestinal mucosa, alleviate stimulation and the damage of ethanol, protection and plerosis function are played in the position of having damaged gastrointestinal mucosa.
Summary of the invention
The purpose of this invention is to provide a kind of hyaluronic Medicament for Alcoholism combination that contains, this combination prescription is simple, and the effect of relieving the effect of alcohol is obvious, has no side effect.
The basic composition of Medicament for Alcoholism combination of the present invention is hyaluronic acid and active carbon.Wherein, hyaluronic acid is a kind of direct-connected polymeric acidic mucopolysaccharide, and it can form network structure after absorbing moisture, harmful substances such as absorption ethanol; Hyaluronic acid also can be dispersed in the space of active carbon, utilizes the gap structure of active carbon and the purpose that hyaluronic network structure reaches harmful substances such as dual absorption and collaborative absorption ethanol, after the absorption, gets rid of external by intestinal.In addition, hyaluronic acid has the mucosa protective effect, can protect gastrointestinal mucosa to avoid the stimulation and the damage of ethanol, and the gastrointestinal mucosa that has damaged is also had protection and plerosis function.
Medicament for Alcoholism combination of the present invention can also contain other active component and adjunct ingredient.Wherein, other active component are meant that except that hyaluronic acid and active carbon other have the material that relieves the effect of alcohol and be worth.Adjunct ingredient is meant excipient, stabilizing agent, antiseptic, antioxidant, emulsifying agent, correctives, coating materials of medicine and field of food routine etc.
Medicament for Alcoholism combination of the present invention can be made various oral formulations by conventional method, comprises tablet, granule, oral liquid, capsule, soft capsule etc.
Its usage and dosage of Medicament for Alcoholism combination of the present invention is: in 100 gram Medicament for Alcoholism combinations, wherein hyaluronic acid can be 0.001～99.99 gram, active carbon 0.001～99.99 gram, and other active substances are an amount of, right amount of auxiliary materials.
Advantage of the present invention is: utilize the huge gap structure of hyaluronic macromolecular network structure and active carbon can dual absorption ethanol, HA is dispersed in the active carbon space also can work in coordination with absorption ethanol, thereby makes absorption safer thoroughly.In addition, hyaluronic acid has the mucosa protective effect, can effectively protect stimulation and the damage of ethanol to gastrointestinal mucosa.Medicament for Alcoholism combination of the present invention will be relieved the effect of alcohol, protect and repair gastrointestinal mucosa and be combined, and wine is preceding or take the equal highly significant of effect after drinking, be a kind of ideal solution medicated wine combination, can be used to be prepared into the sobering preparation that has very much the development and application prospect.
Because the many forms with its salt of hyaluronic acid are used, so the hyaluronic acid of Medicament for Alcoholism of the present invention combination comprises hyaluronic acid and salt thereof, hyaluronate sodium etc. for example.
The specific embodiment of the invention
Embodiment 1:
By hyaluronic acid Medicament for Alcoholism combined preparation Medicament for Alcoholism capsule of the present invention, its usage and dosage is in 100 gram capsules, and wherein hyaluronate sodium 0.5 gram, active carbon 50 restrain, starch slurry is an amount of, food coloring is an amount of.Insert in the capsulae vacuus, promptly by conventional method.
Embodiment 2:
By hyaluronic acid Medicament for Alcoholism combined preparation Medicament for Alcoholism tablet, its usage and dosage is in 100 gram tablets, and wherein hyaluronate sodium 0.5 gram, active carbon 20 restrain, starch slurry is an amount of, starch is an amount of, magnesium stearate is an amount of, dried starch is an amount of.Make tablet by the conventional method pelletizing press sheet.
Experimental study data of the present invention
The investigation project: the present invention's combination gives the influence of alcohol concentration in ethanol (ethanol) bleeding from anus to mouse stomach
Sample preparation: (1) gets hyaluronate sodium 0.1 gram, active carbon 4 grams, and mix homogeneously is standby, as trial target.(2) get active carbon 4 grams, starch 0.1 gram, mix homogeneously is standby, in contrast product.
Method: get 30 of mices and be divided into 3 groups at random, test fasting in preceding 12 hours, can freely drink water.The A group does not give any Medicament for Alcoholism, as blank, B group and C group are irritated stomach respectively and are given reference substance, trial target 2g/kg of the present invention, behind the 20min, all irritate stomach for 3 groups and give 2.5g/kg ethanol, and in 30,60,120,240min socket of the eye vein gets blood, adopts the alcohol concentration in the gas chromatography determination blood.
The results are shown in Table 1.
The antialcoholism action (to the mice influence of blood-alcohol concentration after drinking) of table 1 Medicament for Alcoholism combination of the present invention
Group The concentration of ethanol (mg/ml) in the blood
30min 60min 120min 240min
Blank active carbon reference substance trial target of the present invention 4.01±0.18 3.48±0.11 △ 2.87±0.06 △* 2.72±0.13 2.47±0.08 △ 2.21±0.04 △* 2.20±0.22 1.63±0.09 △ 1.36±0.02 △* 1.30±0.07 0.69±0.12 △ 0.28±0.08 △*
△: compare P＜0.001 with the blank group; *: compare P＜0.001 with simple active carbon group
The result shows that trial target of the present invention all can significantly reduce the mice concentration of blood alcohol after drinking with simple active carbon reference substance, and trial target of the present invention has more obvious advantage, significantly is better than simple active carbon group.

Claims (4)

1. one kind contains hyaluronic Medicament for Alcoholism compositions, it is characterized in that, this Medicament for Alcoholism compositions basic composition is hyaluronic acid and active carbon, wherein in 100 gram said compositions, contain hyaluronic acid 0.001～99.99 gram, contain active carbon 0.001～99.99 gram.
2. one kind as claimed in claim 1ly contains hyaluronic Medicament for Alcoholism compositions, it is characterized in that, on the basis of said composition basic composition, adds conventional adjuvant: stabilizing agent, antiseptic, antioxidant, emulsifying agent, correctives, coating materials.
3. one kind as claimed in claim 1 or 2ly contains hyaluronic Medicament for Alcoholism compositions, it is characterized in that said composition is prepared into various oral formulations by conventional method.
4. one kind as claimed in claim 3ly contains hyaluronic Medicament for Alcoholism compositions, and wherein oral formulations is tablet, granule, oral liquid, capsule, soft capsule.
CNB2005100933419A 2005-08-26 2005-08-26 Alcohol-neutralizing agent composition containing hyaluronic acid Expired - Fee Related CN100377718C (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CNB2005100933419A CN100377718C (en) 2005-08-26 2005-08-26 Alcohol-neutralizing agent composition containing hyaluronic acid
JP2008527293A JP2009505992A (en) 2005-08-26 2006-08-25 Drunkenness reducing composition comprising hyaluronic acid and activated carbon
PCT/CN2006/002190 WO2007022734A1 (en) 2005-08-26 2006-08-25 A composition for alleviating a hangover comprising hyaluronic acid and activated carbon

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNB2005100933419A CN100377718C (en) 2005-08-26 2005-08-26 Alcohol-neutralizing agent composition containing hyaluronic acid

Publications (2)

Publication Number Publication Date
CN1732981A CN1732981A (en) 2006-02-15
CN100377718C true CN100377718C (en) 2008-04-02

Family

ID=36075736

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2005100933419A Expired - Fee Related CN100377718C (en) 2005-08-26 2005-08-26 Alcohol-neutralizing agent composition containing hyaluronic acid

Country Status (3)

Country Link
JP (1) JP2009505992A (en)
CN (1) CN100377718C (en)
WO (1) WO2007022734A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9051456B2 (en) 2005-01-27 2015-06-09 Seikagaku Corporation Agent for drug clearance and accelerator for drug clearance
CN103043661B (en) * 2012-12-12 2014-11-05 承德鑫永晟炭业有限公司 Method for preparing active carbon for relieving or neutralizing effect of alcohol
CN111956713B (en) * 2020-09-03 2021-10-15 华熙生物科技股份有限公司 Hangover-alleviating and liver-protecting composition containing hyaluronic acid and application thereof
CN112725128A (en) * 2021-03-05 2021-04-30 华熙生物科技股份有限公司 White spirit compound spirit, preparation method and method for reducing drunkenness degree

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1280831A (en) * 1999-07-14 2001-01-24 阎小君 Application of activated carbon as sobering-up agent

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1049006C (en) * 1996-12-27 2000-02-02 中国人民解放军第三军医大学 Health-care wine using N-acetyl-D-aminoglucose as additives
CN1188110C (en) * 2003-07-10 2005-02-09 凌沛学 Skin cleaning cosmetics containing active carbon, transparent acid and heparin

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1280831A (en) * 1999-07-14 2001-01-24 阎小君 Application of activated carbon as sobering-up agent

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
透明质酸（HA）的国内外研究现状. 罗瑞明.宁夏农学院学报，第22卷第1期. 2001 *
透明质酸在保健品中的应用. 郭学平等.中国生化药物杂志，第23卷第1期. 2002 *

Also Published As

Publication number Publication date
WO2007022734A1 (en) 2007-03-01
CN1732981A (en) 2006-02-15
JP2009505992A (en) 2009-02-12
WO2007022734A8 (en) 2008-03-20

Similar Documents

Publication Publication Date Title
Bartram Bartram's encyclopedia of herbal medicine
ES2734251T3 (en) Formulation for the treatment of IBS
WO2008034316A1 (en) Compound preparation capable of reducing oxidative stress rapidly and the preparative method thereof
CN106667915B (en) It is a kind of for treating the scutelloside aluminium dry suspensoid agent of grice diarrhoea
CN100377718C (en) Alcohol-neutralizing agent composition containing hyaluronic acid
BR112015011699A2 (en) herbal supplement and its uses and method for treating bloating, constipation and / or weight gain in a human subject
CN104069391B (en) A kind of Chinese medicine composition for treating gout and hyperuricemia and preparation method thereof
CN103768351A (en) Traditional Chinese medicine composition for treating necrotic enteritis and preparation method thereof
CN105232588B (en) A kind of health food and preparation method with protection alcoholic liver injury effect
CN114569686A (en) Anti-alcohol composition, tablet with anti-alcohol effect and preparation method thereof
CN100450532C (en) Chinese medicinal formulation for treating children's hyperkinetic syndrome
CN103610841A (en) Method for treating stomatitis of bamboo rats
CN110201098B (en) Compound propolis composition for treating dysentery of livestock and poultry as well as preparation method and application thereof
CN1220496C (en) Bougie for treating virus hepatitis and preparing method thereof
JP2011168523A (en) Agent for alleviating symptom attributable to premenstrual syndrome and food and beverage containing the same
CN101584750B (en) Compound fig preparation
CN113995809B (en) Medicine for improving intestinal micro-ecological disorder of children
CN105030954B (en) A kind of composition, preparation, preparation method and applications for treating grice diarrhoea
CN109258976A (en) Chinese medicine additive in one breeding hen feed
CN117244037B (en) Composition for preventing and treating calf transfer transportation stress and preparation method thereof
CN108014237A (en) A kind of pharmaceutical composition for treating bone split or fracture and its preparation method and application
JPH06107553A (en) Composition having analgesic function
CN106177269A (en) The pharmaceutical composition of quick curing oral keritonocytes, preparation method and application
US20220175865A1 (en) Traditional chinese medicine compound composition with anti-anxiety effect and preparation method and applications thereof
Maleki et al. Comparison of the effect of polyethylene glycol 40% and fig syrups on the treatment of chronic functional constipation in children: A randomized clinical trial

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20080402

Termination date: 20190826

CF01 Termination of patent right due to non-payment of annual fee